Researchers from the University of Toronto recently examined some of the health benefits of Jardiance (empagliflozin). They found that the drug reduces major heart problem risks and also slows down the progression of kidney disease when patients have both type 2 diabetes and peripheral artery disease.
During the study, data was compared between type 2 diabetes patients with and without peripheral artery disease. While some patients received a daily dose of Jardiance, others received a placebo. At the end of the study it was found that the patients who took the Jardiance for an average of 3.1 years experienced reductions in heart complications, cardiovascular mortality, and neuropathy. They also experienced reductions in all-cause mortality.
These findings were published in Circulation on November 13, 2017.